25.04.2024  19:06:01 Zm. - Wolumen Bid17:35:23 Ask17:35:23 Kapitalizacja Rynkowa St. dywidendy Wskaźnik C/Z
268,25USD - 2 462
Obrót: 173 778,10
-Wolumen Bid: - -Wolumen Ask: - 172,03 mldUSD 2,70% 25,49

Opis działalności

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
 

Zarząd & Rada nadzorcza

CEO
Robert Bradway
Zarząd
Peter H. Griffith, Annalisa Pizzarello, Anton Rabushka, Arleen Paulino, Darryl Sleep, David A. Piacquad, David M. Reese, Esteban Santos, Gilles Marrache, Ian Thompson, Jean-Charles Soria, Jerry Murry, Jonathan Graham, Judy Gawlik Brown, Lori Johnston, Mark J. Taisey, Mike Zahigian, Murdo Gordon, Nancy Grygiel, Rachna Khosla, Raymond Deshaies, Rob Lenz, Susan Sweeney, Victoria H. Blatter
Rada nadzorcza
Robert A. Bradway, Amy E. Miles, Brian J. Druker, Charles M. Holley Jr., Ellen J. Kullman, Greg C. Garland, Michael V. Drake, R. Sanders Williams, Robert A. Eckert, Ronald D. Sugar, S. Omar Ishrak, Tyler Jacks, Wanda M. Austin
 

Dane firmy

Nazwa: Amgen Inc.
Adres: One Amgen Center Drive,Thousand Oaks, CA 91320-1799, USA
Telefon: +1-805-447-1000
Fax: +1-805-447-1010
E-mail: investor.relations@amgen.com
Internet: www.amgen.com
Przemysł: Służba zdrowia
Sektor: Produkty Medyczne
Podsektor: Zaawansowane Urządzenia Medyczne
Koniec roku finansowego: 31.12
Free float: 76,20%
Data IPO: 17.06.1983

Relacje inwestorskie

Nazwa: -
Telefon: +1-805-447-1060
Fax: -
E-mail: investor.relations@amgen.com

Kalendarz korporacyjny

Tydz. 47 | 18.11.2024 Record Date
Tydz. 47 | 18.11.2024 Wcześniejsza dywidenda
Tydz. 50 | 09.12.2024 Wypłata Dywidendy